Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for BCRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 1994. Start Trial.
Date Value
December 31, 2025 329.88M
December 31, 2024 -52.02M
December 31, 2023 -95.14M
December 31, 2022 -161.85M
December 31, 2021 -142.16M
December 31, 2020 -137.22M
December 31, 2019 -89.58M
December 31, 2018 -92.56M
December 31, 2017 -41.14M
December 31, 2016 -53.44M
December 31, 2015 -13.12M
December 31, 2014 -38.55M
December 31, 2013 -26.53M
December 31, 2012 -37.40M
December 31, 2011 -32.25M
December 31, 2010 -28.55M
Date Value
December 31, 2009 -16.22M
December 31, 2008 -20.87M
December 31, 2007 -25.00M
December 31, 2006 -15.21M
December 31, 2005 -23.35M
December 31, 2004 -18.15M
December 31, 2003 -11.20M
December 31, 2002 -16.36M
December 31, 2001 -10.16M
December 31, 2000 -3.178M
December 31, 1999 -4.918M
December 31, 1998 -4.197M
December 31, 1997 -10.30M
December 31, 1996 -6.821M
December 31, 1995 -7.676M
December 31, 1994 -6.515M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Amgen, Inc. 9.958B
Vertex Pharmaceuticals, Inc. 3.631B
Agenus, Inc. -77.20M
Anika Therapeutics, Inc. 11.19M
Imunon, Inc. -13.90M